Therapeutics Discovery is advancing cancer care
MD Anderson at AACR
At the core of MD Anderson’s approach to patient care is our pioneering basic science and practice-changing translational research. Our unique environment accelerates cancer discoveries faster than ever before by offering leading scientific minds close proximity to the clinics to ease collaboration with our renowned clinicians.
Below is a snapshot of the work our experts are presenting at the 2021 AACR Virtual Annual Meeting. Bookmark this page for updates about next year’s meeting and beyond.
Featured Articles
Novel approach paves the way for vast expansion in the number of drugs targeting osteosarcoma
MD Anderson researchers highlight advances in clinical studies at the AACR Annual Meeting 2021
Early phase clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with RET fusion-positive cancers, high-grade (HGG) and low-grade glioma (LGG) and ovarian cancer.
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes
MD Anderson presentations at AACR
Experts from MD Anderson are presenting over 110 presentations during the first week of the 2021 Virtual AACR Annual Meeting. Build your schedule with presentations highlighting the latest advances from our research teams.
MD Anderson News
Moon Shots Program
MD Anderson’s Moon Shots Program® aims to rapidly and dramatically improve the disease's survival rates and reduce suffering through early detection, research and new treatments.
Learn more about the Moon Shots ProgramTherapeutics Discovery
The Therapeutics Discovery division at MD Anderson was created to eliminate the bottlenecks that hamper traditional drug development.
Consisting of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts, our team develops small molecule drugs, biologics and cellular therapies. We're inspired by the needs of our patients and guided by the expertise of the center’s clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.
Learn more about Therapeutics Discovery